SHANGHAI – Six months after London-based Glaxosmithkline plc officially apologized to the Chinese government for bribing non-government personnel, a GSK spokesperson confirmed to BioWorld Asia that more than 100 employees have left the China office for violating the company's code of conduct.
HONG KONG – Expansion among Chinese biotech companies China Biologic Products Inc. (CBPO) and Wuxi Pharmatech (Cayman) Inc. that recently announced full-year 2014 results has ranged from fast to too fast – with the former seeing a more than doubling of its share price and the latter watching its shares tumble over the past year.
Thomson Reuters analysts have disclosed 10 deals – five biopharma licensing and five M&A deals concluded in 2014 – as candidates for the Breakthrough Alliance Awards, with voting now open and the winner to be announced at this year's Allicense meeting in San Francisco.
HONG KONG – Known already as the first China-manufactured biologic used in U.S. trials, HIV candidate ibalizumab (TMB-355) won FDA breakthrough therapy designation, which could substantially accelerate the product's launch.
SHANGHAI – The evolving story of CASI Pharmaceuticals Inc. is about a Nasadaq-listed firm hoping for a fresh start as a China-focused oncology company without letting go of its American roots.
HONG KONG – A study led by Singaporean researchers has identified a potent new antibody against the dengue virus, a minimal amount of which is required to neutralize it, which is an important finding that may lead to the development of effective new treatments or vaccines.
SHANGHAI – Making a strong move to enter China's cardiovascular (CDV) market, Shanghai-based Eddingpharm Co. Ltd. inked a deal with Amarin Corp. plc, of Dublin, to bring Vascepa to Greater China. Amarin will receive a nonrefundable $15 million up-front payment, while the total deal is valued at $169 million in milestones and tiered sales royalties.
TAIPEI, Taiwan – Companies across Southeast Asia are taking multiple steps to develop or attract more innovation and power their biotechnology industries.
Twi Pharmaceuticals Inc., of Taipei, Taiwan, and Teva Pharmaceuticals Industries Ltd., of Jerusalem, reached an agreement that will transfer the U.S. sales and distribution rights of Twi's generic versions of Megace ES (megestrol acetate oral suspension, 625 mg/ 5 ml) and Lidoderm (lidocaine patch, 5 percent) from Teva to Twi.
SHANGHAI – The five month old GPCR Consortium – which brings together industry and academics to explore the G protein-coupled receptors (GPCRs) family of proteins – has added two new pharmaceutical members to its fold. It now counts Novo Nordisk AS and Merck & Co. Inc. as members in addition to founding members Amgen Inc., Ono Pharmaceutical Co. Ltd. and Sanofi SA. The partners provide not just funding to the research consortium's efforts.
RSS